Programme - 11th Int. Workshop on Clin. Pharmacology of HIV Therapy

Program - 11th International Workshop on Clinical Pharmacology of HIV Therapy

Wednesday 7 April		Thursday 8 April		Friday 9 April


Session 5: Drug Interactions (II)
Invited lecture: Antiretroviral-antituberculosis treatment interactions in patients	H. McIlleron		Pres.
Altered plasma levels of nevirapine after commencing rifampicin containing TB regimens in Malawi	M. Chaponda	Abs.	Pres.
The pharmacokinetics of Lopinavir in South African HIV-infected volunteers receiving rifampicin with adjusted doses of Lopinavir/ritonavir.	E. Decloedt	Abs.	Pres.

Round Table discussion: Is Ritonavir The Gold Standard for Pharmacokinetic Enhancement
Round table presentation	R. Bertz		N.A.
Round table presentation	T. Hawkins		N.A.

Session 6: Pharmacokinetics and Pharmacodynamics of Integrase Inhibitors
Evaluation of ritonavir-boosted Elvitegravir PK upon coadministration with a second potent CYP3A inhibitor, ketoconazole	B. Kearney	Abs.	Pres.
Exposure-related effects of unboosted atazanavir on the pharmacokinetics of raltegravir in HIV-1 infected patients	D. Cattaneo	Abs.	Pres.
Population pharmacokinetic and viral dynamic modeling of S/GSK1349572 in patients with HIV infection	J.Zhang	Abs.	Pres.
Modeling and clinical trial simulation to support dose selection of S/GSK1349572 in phase IIB studies	I-H.Song	Abs.	Pres.
Meta-analysis of pharmacokinetic-pharmacodynamic relationship of integrase inhibitors following short-term monotherapy	I-H.Song	Abs.	Pres.

Late Breaker
Comparative plasma and intracellular pharmacokinetics of microdosing and standard dosing of zidovudine with accelerator mass spectrometry	C. Flexner	Abs.	Pres.

Virology Education -
a Medical Education company